CI Investments Inc
NBIX icon

CI Investments Inc’s Neurocrine Biosciences NBIX Stock Holding History

CI Investments Inc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$263K Sell
1,561
-1,026
-40% -$152K ﹤0.01% 720
2026
Q1 		$341K Sell
2,587
-148
-5% -$19.6K ﹤0.01% 535
2025
Q4 		$388K Sell
2,735
-61
-2% -$8.84K ﹤0.01% 535
2025
Q3 		$393K Sell
2,796
-260
-9% -$35.2K ﹤0.01% 559
2025
Q2 		$384K Sell
3,056
-886
-22% -$102K ﹤0.01% 576
2025
Q1 		$436K Sell
3,942
-342
-8% -$43.3K ﹤0.01% 545
2024
Q4 		$585K Buy
4,284
+738
+21% +$91.3K ﹤0.01% 491
2024
Q3 		$409K Buy
3,546
+879
+33% +$121K ﹤0.01% 523
2024
Q2 		$367K Buy
2,667
+29
+1% +$3.98K ﹤0.01% 523
2024
Q1 		$364K Buy
2,638
+1,174
+80% +$160K ﹤0.01% 541
2023
Q4 		$193K Sell
1,464
-270
-16% -$31.1K ﹤0.01% 658
2023
Q3 		$195K Sell
1,734
-244
-12% -$25.7K ﹤0.01% 637
2023
Q2 		$187K Buy
1,978
+1,140
+136% +$111K ﹤0.01% 645
2023
Q1 		$85K Buy
838
+697
+494% +$72.5K ﹤0.01% 776
2022
Q4 		$17K Hold
141
– – ﹤0.01% 1094
2022
Q3 		$15K Sell
141
-1
-0.7% -$101 ﹤0.01% 1080
2022
Q2 		$14K Sell
142
-332
-70% -$30.6K ﹤0.01% 1013
2022
Q1 		$44K Sell
474
-28
-6% -$2.37K ﹤0.01% 974
2021
Q4 		$43K Buy
502
+94
+23% +$8.65K ﹤0.01% 1021
2021
Q3 		$39K Buy
+408
New +$38.5K ﹤0.01% 1001
2020
Q3 		– Sell
-3,565
Closed -$435K – 955
2020
Q2 		$435K Buy
+3,565
New +$394K ﹤0.01% 424

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CI Investments Inc's NBIX Position: Q2 2026 in Review

CI Investments Inc reduced its Neurocrine Biosciences (NBIX) stake by 40% in Q2 2026, selling an estimated $152K and leaving 1,561 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #720.

CI Investments Inc first reported a position in NBIX in Q2 2020 and has held it in 21 quarters since. The position peaked at $585K in Q4 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • CI Investments Inc held 1,561 shares of Neurocrine Biosciences worth $263K as of Q2 2026.
  • CI Investments Inc sold 1,026 Neurocrine Biosciences shares in Q2 2026, an estimated $152K.
  • Neurocrine Biosciences made up ﹤0.01% of CI Investments Inc's portfolio in Q2 2026, its #720 holding.
  • CI Investments Inc first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 21 quarters since.
  • CI Investments Inc's Neurocrine Biosciences position peaked at $585K in Q4 2024.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on CI Investments Inc's 13F filing for Q2 2026, filed 13 Aug 2026.